Replies to post #151357 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

because U.S. market is the most money when it comes to prescription drugs, imo. I have seen similar thing happened in Amarin's Vascepa drug that the management is only focusing on getting their drug approved for CVD diseases in the U.S. first before it reaches out to other countries.

[sentiment_stocks]

Some interesting thoughts in this post. :)

[flipper44]

I just think it's so important to point this out more than once. I take it on "trust" at face value.

"On February 3, the FDA lifted the partial clinical hold which had been in place on the Trial. As previously reported, the Company has been in an ongoing dialog with regulators. The dialog culminated in the FDA lifting the partial hold. As previously announced by the Company, and as the Company also informed the FDA, the Company has closed enrollment and is not going to enroll the last 17 of the planned 348 patients."

PR 2/6/17
https://www.nwbio.com/nw-bio-announces-lifting-clinical-hold-dcvax-l-phase-iii-trial-fda-progression-free-survival-events-reached-overall-survival-events-not-yet-reached/

A nontrusting person might say NWBO was playing word games -- ie. that NWBO intentionally made it sound like the dialogue with other substance resulted in lifting the hold rather than the company closing enrollment. I instead trust that if company really got the hold lifted simply by closing enrollment, they would have clearly stated this and not suggested closing enrollment was merely an additional piece of information collateral to whatever substance the ongoing dialogue contained that resulted in lifting the hold. Because I am trusting them, and not expecting word games. I expect there was substance in the then ongoing dialogue that we are not privy to yet.